Physician profile
Heather Condley
NPI 1194377176
$3,395.33
in general payments reported to CMS, 2019-2025
25 companies · $264 in 2025
The $264 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,164 · 2022: $1,044 · 2023: $816 · 2024: $108 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,187.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $837.08 | 2021 | |
| Abbvie INC. | $827.25 | 2021-2025 | |
| Lilly USA, LLC | $322.36 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $227.15 | 2022-2025 | |
| Novo Nordisk INC | $198.67 | 2021-2024 | Wegovy |
| Biohaven Pharmaceutical Holding Company Ltd. | $175.04 | 2022 | |
| Sanofi-Aventis U.S. LLC | $149.81 | 2021-2023 | |
| Organon LLC | $106.15 | 2022-2025 | Nexplanon |
| Seagen INC. | $79.99 | 2021 | |
| Merck Sharp & Dohme LLC | $66.41 | 2022-2024 | Capvaxive, Vaxneuvance, Gardasil |
| Astellas Pharma US INC | $49.21 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.63 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $37.46 | 2025 | Rexulti |
| Sanofi Pasteur INC. | $34.11 | 2022-2023 | |
| Amgen INC. | $34.09 | 2022-2023 | Repatha, Otezla |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $32.98 | 2025 | Obtryx System - Curved |
| Astrazeneca Pharmaceuticals Lp | $27.59 | 2022-2025 | Airsupra |
| Genmab U.S., INC. | $24.04 | 2021 | |
| Supernus Pharmaceuticals, INC. | $19.16 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.06 | 2022 | |
| Daiichi Sankyo INC. | $18.75 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.19 | 2023 | Livalo, Seglentis |
| Eisai INC. | $15.89 | 2022 | |
| Seqirus USA INC | $15.15 | 2022 | |
| Exact Sciences Corporation | $14.11 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Condley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.